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ABSTRACT
There have been signiﬁcant recent advances in our understand-
ing of the mechanisms that maintain potassium homoeostasis
and the clinical consequences of hyperkalemia. In this article we
discuss these advances within a concise review of the patho-
physiology, risk factors and consequences of hyperkalemia. We
highlight aspects that are of particular relevance for clinical
practice. Hyperkalemia occurs when renal potassium excretion
is limited by reductions in glomerular ﬁltration rate, tubular
ﬂow, distal sodium delivery or the expression of aldosterone-
sensitive ion transporters in the distal nephron. Accordingly,
the major risk factors for hyperkalemia are renal failure, diabe-
tes mellitus, adrenal disease and the use of angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers or
potassium-sparing diuretics. Hyperkalemia is associated with
an increased risk of death, and this is only in part explicable
by hyperkalemia-induced cardiac arrhythmia. In addition to its
well-established effects on cardiac excitability, hyperkalemia
could also contribute to peripheral neuropathy and cause
renal tubular acidosis. Hyperkalemia—or the fear of
hyperkalemia—contributes to the underprescription of poten-
tially beneﬁcial medications, particularly in heart failure. The
newer potassium binders could play a role in attempts to mini-
mize reduced prescribing of renin–angiotensin inhibitors and
mineraolocorticoid antagonists in this context.
Keywords: aldosterone, arrhythmia, hyperkalemia, potassium,
renin–angiotensin
INTRODUCTION
The introduction of new potassium binders (patiromer and zir-
conium cyclosilicate) has refocused attention on hyperkalemia.
There have also been significant recent advances in our under-
standing of themechanisms that maintain potassium homoeosta-
sis and the clinical consequences of hyperkalemia. In this
article we aim to present these recent advances in the context of a
concise review of the pathophysiology, risk factors and conse-
quences of hyperkalemia. We will highlight aspects that are of
particular relevance for clinical practice.
PATHOPHYSIOLOGY OF HYPERKALEMIA
Principles of potassium homoeostasis: a battle waged on
two fronts
The three-pronged response to an acute potassium
load. The extracellular potassium concentration, [Kþ]e, is
kept under tight control to maintain the resting membrane po-
tential (RP) of excitable cells. This control is under continual
threat from two sources of potassium influx. The first is inter-
nal: 98% of total body potassium (3–4 mol) is stored within
cells, predominantly skeletal muscle. The second is external:
our potassium-rich diet. A modern Western diet contains
120mmol potassium per day and throughout most of our
evolutionary history this was a great deal more (300mmol
per day in the palaeolithic diet) [1].
Consequently we have evolved robust mechanisms to defend
against potassium influx into the extracellular space (reviewed
in McDonough and Youn [2]). Without this defence, we would
rarely make it past breakfast: a banana smoothie delivering
35mmol of potassium to an extracellular fluid volume of 12 L
would induce a potentially fatal [Kþ]e increase of 3mM. We
survive the banana smoothie because of a rapid response that
shifts potassium into cells and into the urine. Thus the large in-
tracellular potassium store constitutes a potential threat but is
also a lifesaving buffer.
Recent studies in healthy human subjects have helped to de-
lineate three prongs to the response to a dietary potassium load
[3]. When subjects were administered 35 mmol Kþ, plasma
[Kþ] rose by 0.5mM and was accompanied by increases in
plasma [aldosterone] and renal Kþ excretion (Prong 1: the clas-
sic aldosterone-dependent negative feedback loop). When the
same potassium load was administered as part of a complex
meal, there was no change in plasma [Kþ], probably reflecting
insulin-mediated transcellular potassium shifts (Prong 2).
Despite there being no change in venous plasma [Kþ], there
was an increase in renal potassium excretion, which was not
prevented by treatment with the mineraolocorticoid receptor
(MR) antagonist eplerenone. This provides evidence for an
aldosterone-independent, gut-to-kidney feedforward kaliuretic
signal (Prong 3).
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Although only recently confirmed in humans, this mode of
feedforward control has been known about for several decades
in sheep [4] and has been studied in some detail in rodents [5,
6]. In one particularly meticulous study, potassium loads were
administered to rats via an enteral or intravenous route in such
a way as to induce identical increases in plasma [Kþ]. Enteral
loads elicited a kaliuretic response of greater magnitude [6].
The gut-responsive ‘kaliuretic factor’ has not been identified. It
has been hypothesized to be a peptide hormone or a centrally
mediated reflex [7], but one cannot discount the possibility that
there is no mystery factor and instead the error signal driving
kaliuresis is a small increase in the potassium concentration in
the renal peritubular capillaries, not readily detectable by ve-
nous sampling. Testing a panel of known gut or pituitary pep-
tide hormones did not reveal a likely culprit [6].
Whatever the mechanism(s), the clinical ramifications of
these physiological observations have not been explored fully. Is
hyperkalemia more likely to be provoked by intravenous than
by oral potassium supplements? Could manipulation of diet
composition, rather than mere potassium content per se prevent
hyperkalemia in patients with end-stage renal disease? If we
could determine the molecular basis of the gut potassium ‘sen-
sor’, then could we target this with novel drug therapies?
Chronic potassium homoeostasis: not just aldosterone. Plasma
[Kþ] is controlled by aldosterone in a negative feedback loop.
Aldosterone is synthesized by aldosterone synthase (AS) in the
adrenal cortex in response to high [Kþ]e and angiotensin II. It
acts in the distal nephron to increase the activity of sodium
(Na)–K–adenosine triphosphatase (ATPase) pumps and epi-
thelial sodium channel (ENaC), renal outer medullary potas-
sium (ROMK) and large (‘big’) potassium (BK) channels to
promote kaliuresis [8]. (We discuss the molecular basis of renal
potassium excretion in more detail below.)
Aldosterone is the dominant factor regulating plasma [Kþ],
but it is not the only one. Two mouse models have been used to
explore the extent to which aldosterone is necessary for potas-
sium homoeostasis: AS-null mice (which are unable to synthe-
size aldosterone) and kidney-specific MR-null mice (which
possess kidneys that are unable to respond to aldosterone sig-
nalling) [9, 10]. Both models develop hyperkalemia when chal-
lenged with supraphysiological potassium loads. However, AS-
null mice can maintain a normal plasma [Kþ] in the face of
physiological (2%) dietary Kþ, demonstrating that aldosterone-
independent pathways can stimulate kaliuresis in this context.
Chronic potassium homoeostasis is maintained not only by
fine-tuning renal Kþ excretion, but also bymodulating transcel-
lular potassium shifts. The magnitude of (net) transcellular po-
tassium shifts can be measured experimentally using a
‘potassium clamp’, in which the rate that potassium exits the
vascular space is inferred from the rate of potassium infusion
required to clamp plasma [Kþ] at a constant level. This ap-
proach was used in the rat to demonstrate key features of the in-
sulin–potassium homoeostatic system [11]. After short-term
potassium depletion, insulin-induced potassium shifts were
markedly reduced (without any change in insulin-mediated
glucose clearance). Thus the gain of this system is modified by
potassium status and is regulated independently from insulin–
glucose homoeostasis.
It’s complicated! Of course, the above model is an over-
simplification. Potassium homoeostasis is not independent
from the many other facets of systemic physiology and we are
continually learning about new pieces in the puzzle. One partic-
ularly intriguing story that has emerged in recent years is that of
the circadian influences on potassium excretion. Renal potas-
sium excretion follows a circadian rhythm, being highest
around noon and lowest around midnight. Renal tubular cells
possess an intrinsic molecular clock that is now well-character-
ized. This is synchronized with the central (brain) clock, in part
through glucocorticoid signalling [12].
It follows that the risk of hyperkalemia is almost certainly
influenced by the timing of meals, potassium loads and drug
administrations. Could this be exploited to minimize the risk of
hyperkalemia in high-risk patients?
Hyperkalemia from transcellular potassium shifts
The huge size of the intracellular potassium store means that
transcellular shifts can have large and rapid effects on plasma
[Kþ]. Potassium shifted from the intra- to the extracellular
space are induced by acute metabolic acidosis and opposed by
insulin and b-adrenergic signalling [13]. Widespread cell death
(as in tumour lysis or rhabdomyolysis) may also release potas-
sium from the intracellular space.
Transcellular shifts can be quantitatively more important
than external potassium load, as was demonstrated by random-
ized controlled trials (RCTs) of perioperative intravenous fluid
therapy in kidney transplant recipients. Patients randomized to
receive 0.9% sodium chloride (NaCl; containing no potassium)
had a greater incidence of hyperkalemia than those randomized
to receive plasmalyte-148 (containing 4mM potassium) [14,
15]. The likely explanation for this apparent paradox is that
chloride-rich 0.9% NaCl induces metabolic acidosis, whereas
buffered plasmalyte-148 does not.
Hyperkalemia from defective potassium excretion in the
distal nephron
Ninety percent of excreted potassium exits via the kidneys
and the kidneys have a remarkable capacity to increase potas-
sium excretion in the face of potassium excess [16].
Consequently hyperkalemia is almost never encountered clini-
cally in the context of normal renal function and a normal adre-
nal–kidney axis.
Physiological control of potassium excretion is exercised in
the aldosterone-sensitive distal nephron (reviewed in
McDonough and Youn [2] andWelling [8]). An understanding
of the molecular pathways of potassium excretion can help in
understanding the clinical insults that induce hyperkalemia.
Potassium is secreted through renal tubular cells via the so-
dium–potassium pump in the basolateral membrane and at
least four different types of ion channels in the apical mem-
brane. The most well-studied of these are the ROMK channel
and the BK channel.
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ROMK channels and the coupling of sodium and
potassium transport in the distal nephron. ROMK chan-
nels are expressed in principal cells alongside the ENaC. This
arrangementmeans that potassium excretion in the distal neph-
ron is coupled to sodium reabsorption. Naþ reabsorption
through the ENaC generates a lumen-negative potential,
favouring Kþ excretion. When sodium influx through the
ENaC is high (e.g. in response to aldosterone signalling), potas-
sium efflux is also high. Conversely, when sodium influx is low
(as in volume depletion, when sodium delivery to the distal
nephron is limited), potassium efflux is diminished. In potas-
sium excess, hyperkalemia is avoided because ROMK is upregu-
lated through aldosterone-dependent and -independent
pathways [8].
Sodium delivery to the distal nephron is therefore an impor-
tant determinant of potassium excretion. Except in extreme vol-
ume depletion, tubuloglomerular feedback ensures that a
constant load of NaCl is delivered to the post-macular renal tu-
bule [17]. Therefore the supply of sodium to the ENaC in the
connecting tubule and collecting ducts is determined primarily
by the activity of the distal electroneutral sodium reabsorption
pathways: sodium chloride cotransporter (NCC) in the distal
convoluted tubule and the sodium-dependent Cl/HCO3
 ex-
changer (NDCBE) in the b-intercalated cell, functionally cou-
pled with pendrin [18]. Reciprocal studies in mice show the
importance for potassium homoeostasis of coordinated cross-
talk between these distal sodium transporters: double genetic
deletion of NCC and NDCBE caused hypokalemia in mice,
which could not be explained solely on the basis of activation of
the renin–angiotensin–aldosterone system [19]: the expression
of ENaC, ROMK and BK proteins was increased as was the
natriuretic effect of amiloride. Conversely, transgenic mice car-
rying the Q562E mutation inWNK4 that causes pseudohypoal-
dosteronism type II (PHAII) mutation were hyperkalemic due
to combined activation of NCC and pendrin/NDCBE and ‘re-
duced’ potassium secretion by the principal cell [20].
The balance between electroneutral and electrogenic distal
Naþ reabsorption determines net potassium excretion. This
physiological switch is manipulated by the mechanisms that
maintain potassium homoeostasis. Potassium channels (Kir4.1)
in the basolateral membranes of distal convoluted tubule cells
act as ‘potassium sensors’, activating NCC in response to potas-
sium depletion [21, 22]. Furthermore, NCC activity can be
controlled by phosphorylation/dephosphorylation of critical
residues in the N-terminus. Dephosphorylation, suppressing
NCC activity, helps to enhance potassium excretion after a
potassium-rich meal: the effector arm of the gut–kidney feed-
forward loop [2]. Dephosphorylation is also observed following
acute hyperkalemia in the rat [23], and the urinary abundance
of phosphorylated NCC is negatively correlated with plasma
[Kþ] in humans [24]. NCC is directly activated by aldosterone
[25–27] but can also be controlled by aldosterone-independent
mechanisms. For example, potassium restriction stimulates
NCC activity in kidney-specific MR-null mice [10].
BK channels and their regulation by urinary flow rate and
alkalinization. BK channels are expressed in principal and
intercalated cells. These are activated by high tubular flow rates
and thus mediate flow-induced potassium secretion. The ‘flow
sensor’ has recently been determined: bending of the primary
cilium on the principle cell opens transient receptor potential
vanilloid type 4 channels, causing an influx of calcium that in
turn activates BK channels [28]. BK channels are also upregu-
lated in response to potassium loading. The mechanism here is
fascinating. BK channels are formed from two subunits, both of
which are required for channel activity. Aldosterone upregu-
lates the expression of the a-subunit and bicarbonate upregu-
lates expression of the b-subunit. Therefore it has been argued
that regulation of BK channel activity is critical in the response
to a ‘Palaeolithic’ low-sodium, high-potassium, alkaline diet [8].
In support of this, mice fed a low-sodium, high-potassium diet be-
come hyperkalemic when they are also given an acid load [29].
Clinical implications. These molecular processes explain
why hyperkalemia invariably occurs in response to stimuli that
limit any of five key parameters (Figure 1): (i) glomerular filtra-
tion rate, (ii) tubular flow rate, (iii) sodium delivery to the distal
nephron, (iv) the expression of potassium and sodium channels
in the apical cell membrane and the sodium–potassium pump
in the basolateral membrane (controlled by aldosterone signal-
ling) and (v) urinary pH.
In clinical practice, the first three of these are frequently en-
countered together, explaining the pathogenesis of hyperkale-
mia in acute kidney injury (AKI). The normal physiological
response to volume depletion drives upregulation of aldoste-
rone synthesis, so that any reductions in (i)–(iii) are offset by
increases in (iv), maintaining potassium homoeostasis.
Hyperkalemia ensues when this response is prevented, for ex-
ample, by renin–angiotensin system (RAS) inhibitors or MR
blockers.
Hyperkalemia can occur when NCC activity is stimulated,
leading to reduced reabsorption of sodium through the electro-
genic pathway. The archetypal example of this is type II pseudo-
hypoaldosteronism (Gordon’s syndrome), in which inherited
mutations in the Wnk-SPAK kinase cascade or the KLHL3–
CUL3 ubiquitin ligase complex that regulates it lead to the con-
stitutive phosphorylation (and therefore activation) of NCC
[30]. More commonly, this syndrome, characterized by hyper-
tension, hyperkalemia and hyperchloremic acidosis, may be ac-
quired by renal transplant recipients taking the calcineurin
inhibitor tacrolimus. Tacrolimus indirectly activates NCC [31]
by inactivating negative regulators in the KLHL3–CUL3 ubiqui-
tin ligase complex [32]. Alternatively, hyperkalemia may occur
when ENaC activity is inhibited by drugs (e.g. amiloride, tri-
methoprim and pentamidine) in adrenal disease (because of
impaired aldosterone synthesis) or by heritable mutations inac-
tivating ENaC orMR (type I pseudohypoaldosteronism).
Hyperkalemia from defective extrarenal potassium
excretion
In patients with healthy kidneys, the colon excretes 10% of
ingested potassium; this route of excretion becomes relatively
more important in patients with advanced renal failure. In a
RCT comparing spironolactone, losartan and placebo in combi-
nation with lisinopril in patients with diabetic nephropathy,
spironolactone caused greater elevations in serum [Kþ] than
iii4 R.W. Hunter and M.A. Bailey
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losartan, despite exerting similar effects on urinary potassium
excretion, suggesting a significant effect of spironolactone on
extrarenal potassium excretion [33].
For some anuric patients, the colon undoubtedly makes a
clinically significant contribution to total potassium excretion
[34]. However, colonic potassium excretion probably makes a
modest contribution to systemic potassium homoeostasis in
most patients with end-stage renal disease. There have been
several small RCTs of mineralocorticoid antagonist therapy in
oligoanuric hemodialysis patients. By and large, these have
shown that mineraolocorticoid antagonists do increase the risk
of hyperkalemia, but this is rarely severe enough to warrant dis-
continuation of therapy [35–37].
RISK FACTORS FOR HYPERKALEMIA
Quantitatively important risk factors
From the above, it is clear that the major risk factors for
hyperkalemia are renal impairment - either AKI or advanced
chronic kidney disease (CKD) - and any acquired or inherited
defects in potassium excretion in the distal nephron. In CKD,
hyperkalemia is typically encountered after the estimated glo-
merular filtration rate (eGFR) drops below 15mL/min [38].
The risk factors for hyperkalemia were studied in a meta-
analysis of data from >1.2million individuals with CKD [39].
The risk of hyperkalemia (K> 5.5mM) was strongly correlated
with eGFR across the entire range of kidney function (from
eGFR 15 to 105mL/min). A decrease in eGFR of 15mL/min ap-
proximately doubled the odds of hyperkalemia [39].
Albuminuria was also a risk factor, but the association was far
weaker (odds ratio for hyperkalemia< 2 even in heavy albu-
minuria) [39]. Other risk factors for hyperkalemia included
male sex; non-black race; lower body mass index; smoking, his-
tory of diabetes mellitus, coronary heart disease or stroke and
use of angiotensin-converting enzyme inhibitor (ACEi), angio-
tensin receptor blocker (ARB) or potassium-sparing diuretics.
Unsurprisingly, the use of thiazide or loop diuretics was
protective.
Drug therapies as risk factors for hyperkalemia
The medications associated with hyperkalemia are listed in
Table 1.
RAS blockade. For most patients, RAS blockade with a sin-
gle agent confers a low risk of hyperkalemia. Furthermore,
patients at risk of hyperkalemia can be identified by the pres-
ence of the classical risk factors discussed above. A risk score,
combining information from six risk factors (male sex, baseline
[Kþ], eGFR, diabetes, heart failure and use of potassium-
sparing diuretics) performed well at predicting hyperkalemia
after initiation of RAS inhibitors (RASis) in Swedish and
American populations [44].
However, there are significant risks of hyperkalemia when
the RAS is targeted with multiple agents. The risks of dual
blockade were revealed by large RCTs: Aliskiren Trial in Type 2
Diabetes Using Cardiorenal Endpoints (ALTITUDE), Veterans
Affairs Nephropathy in Diabetes (VA NEPHRON-D) and
Ongoing Telmisartan Alone and in Combination with Ramipril
Global Endpoint Trial (ONTARGET) [45–47]. The first two tri-
als, both conducted in patients with type 2 diabetes, were termi-
nated prematurely because of safety concerns. Hyperkalemia
(>6mM) was significantly more common in the dual-blockade
group than in a single-blockade control group (11.2% versus
7.2% in ALTITUDE and 9.9% versus 4.4% in VA NEPHRON-
D). This effect was also present but less marked in
ONTARGET, which studied a population with less advanced
renal disease and<40% prevalence of diabetes.
MR antagonists. Due to the pivotal role of aldosterone in
the control of potassium homoeostasis, MR antagonist (MRA)
therapy is a risk factor for hyperkalemia. In a meta-analysis of
RCTs conducted in >16 000 patients with heart failure or after
myocardial infarction, hyperkalemia (defined by the individual
FIGURE 1: Pathogenesis of hyperkalemia: mechanisms in the distal nephron. Factors that can cause hyperkalemia are in red text. These
perturb one or more of ﬁve key variables: glomerular ﬁltration, urine ﬂow, sodium delivery to the distal nephron, expression of aldosterone-
sensitive ion channels and transporters and urinary pH. PHAI, type I pseudohypoaldosteronism; CNI, calcineurin inhibitor.
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studies as [Kþ] >5.5 or 6.0mM) occurred in 4.3% of patients
allocated to placebo versus 9.3% of patients allocated to
MRAs [48].
Famously, dangerous hyperkalemia became more common
after the publication of the Randomized Aldactone Evaluation
Study (RALES) study, which demonstrated a morbidity and
mortality benefit from spironolactone therapy in heart failure
with reduced ejection fraction (HFrEF). Large-scale data link-
age in a Canadian population revealed that the rates of both
hospitalization for hyperkalemia and in-hospital hyperkalemia-
related mortality more than doubled after the publication of
RALES in September 1999 [49].
In animal models and in Phase 1/2 clinical trials, novel non-
steroidal MR antagonists have a more favourable therapeutic
index than spironolactone or eplerenone—that is, they carry a
lower risk of hyperkalemia at therapeutic doses in heart failure
and proteinuric CKD [50, 51].
Other drugs. Large data-linkage studies are helping to quan-
tify the risk of hyperkalemia associated with other medications.
For example, trimethoprim prescription for urinary tract infec-
tion (compared with alternative antibiotics) was associated with
a small increase in the odds of hyperkalemia in patients >65
years of age. For every 1000 infections, treatment with trimeth-
oprim rather than amoxicillin results in one to two cases of
hyperkalemia in an unselected population. In keeping with the
pervasive concept that risk is potentiated when drugs that pre-
dispose to hyperkalemia are prescribed in combination in
patients also taking RAS inhibitors or MRAs, trimethoprim
would cause18 additional cases of hyperkalemia [52].
Other risk factors
Diabetes mellitus is a risk factor for hyperkalemia (indepen-
dent of RAS blockade) because of its association with hyporeni-
nemic hypoaldosteronism. This state is presumed to arise from
decreased sympathetic drive to renin secretion (in diabetic au-
tonomic neuropathy), decreased capacity to synthesise renin
because of injury to the juxtaglomerular apparatus (in afferent
arteriolar hyalinosis and diabetic nephropathy) and a decreased
volume stimulus to renin release because of chronic renal salt
retention [53, 54].
Hyperkalemia may also arise, via some unknown mecha-
nism, in the ‘hungry bones’ syndrome after parathyroidectomy
for secondary hyperparathyroidism. The risk may be particu-
larly high in patients who have been treated with cinacalcet
[55].
Risk factors for hyperkalemia in dialysis patients
Patients receiving dialysis for end-stage renal failure form a
group worthy of special consideration, because the risk of
hyperkalemia can be influenced by variables in dialysis therapy.
For example, in patients receiving maintenance hemodialysis,
serum [Kþ] is influenced by time since the last dialysis therapy,
being higher after a 3-day than a 2-day gap (reviewed in Rhee
[56]). Interestingly however, the potassium content of the he-
modialysis fluid does not appear to be a major determinant of
serum [Kþ], as measured 2 or 3 days later before the next dialy-
sis session [57].
CONSEQUENCES OF HYPERKALEMIA
The most notorious consequence of hyperkalemia is that of po-
tentially fatal cardiac dysrhythmia. However, there are several
other consequences worthy of discussion. Hyperkalemia is as-
sociated with increased mortality (although we do not know
whether hyperkalemia causes increased mortality outside of the
context of cardiac arrhythmia in extreme hyperkalemia).
Consequently, hyperkalemia—or the fear of hyperkalemia—
may prompt changes in prescribing practice (e.g. avoiding RAS
blockade and MRAs). Finally, recent data show that hyperkale-
mia can cause renal tubular acidosis and may contribute to pe-
ripheral neuropathy in CKD patients.
Mortality: epidemiology
Large observational studies demonstrate an association be-
tween hyperkalemia and an increased risk of death [39, 58, 59].
In a meta-analysis of data from >1.2 million individuals with
CKD, serum [Kþ] exhibited a U-shaped relationship with all-
cause and cardiovascular mortality, with a nadir at 4.2mM.
The adjusted hazard ratio for all-cause mortality was 1.22 for
[Kþ]>5.5mM [39]. This association persisted after adjustment
for a large number of covariates [39, 60]. However, as there
have been no large interventional studies testing the effects of
potassium-lowering therapies (or of plasma [Kþ] targets) per se
on mortality, we do not know whether this association is due to
residual confounding (i.e. whether or not mild-to-moderate
hyperkalemia causes an increased risk of death).
The most plausible mechanism whereby hyperkalemia could
cause death is by the induction of fatal cardiac arrhythmia. In
patients with acute myocardial infarction, hyperkalemia did in-
deed increase the risk of ventricular arrhythmias [58]. However,
there are some observations to suggest that any mortality risk
associated with hyperkalemia cannot be solely attributed to
Table 1. Drug causes of hyperkalemia
Mechanism Drug
Defective aldosterone signalling
Impaired renin production b-Blockers and NSAIDs
Impaired renin–angiotensin
signalling
Aliskiren, ACEis and ARBs
Impaired aldosterone synthesis Heparin [40] and ketoconazole
MR blockade Spironolactone and eplerenone
Defective distal electrogenic sodium reabsorption
ENaC blockade Amiloride, triamterene, trimetho-
prim [41–43], pentamidine and
lithium
NCC activation CNIs [31]
Cellular Kþ translocation
Changes in transcellular
transporters
a-Agonists, b-blockers, digoxin,
succinylcholine, isoﬂuorane, minox-
idil and somatostatin
Solvent drag in osmotic shifts Mannitol
Exogenous potassium load
High-potassium content Penicillins (intravenous) [40]
CNI, calcineurin inhibitor; NSAIDs, non-steroidal anti-inﬂammatory drugs.
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arrhythmogenic death. For example, in a racially diverse popu-
lation of community-dwelling older adults, hyperkalemia was
not associated with sudden cardiac death, whereas it was associ-
ated with death from cancer and other non-cardiac causes [60].
Moreover, adverse outcomes have been associated with higher
plasma [Kþ] values that remain well within the reference range
[39, 60, 61]. Therefore we still have much to learn about the
methodology of epidemiological studies in this area and/or the
pathogenic consequences of hyperkalemia [62].
Cardiac dysrhythmia: mechanism
An increase in [Kþ]e has several consequences for the myo-
cardial action potential (AP; Figure 2). These are driven by de-
polarization of the resting (RP) and activation of inward
rectifier potassium channels (carrying currents IK1 and IKr).
Depolarization of the RP exerts a biphasic effect on myocar-
dial excitability and conduction velocity [63–65]. Modest
increases in [Kþ]e (up to8mM) increase excitability and con-
duction velocity as the RP moves closer to the threshold poten-
tial for AP initiation [via activation of voltage-gated Naþ
channels (NaV1.5)]. Further increases in [K
þ]e reduce conduc-
tion velocity or even prevent AP initiation (at [Kþ]e 14mM),
due to the steady-state inactivation of NaV1.5 channels at depo-
larized membrane potentials [63, 66]. Activation of
inward rectifier Kþ currents during repolarization (AP Phases 3
and 4) induces rapid repolarization and retards diastolic depo-
larization of Purkinje fibres.
The net effect is that as [Kþ]e rises modestly, the AP duration
shortens, manifesting as peaked T-waves on an electrocardiogram
(ECG), as a mass of myocardium undergoes premature synchro-
nous repolarization [64, 65]. Furthermore, conduction velocity
increases so that cardiac conduction blocks may resolve (hence
why cardiologists request measures to increase plasma [Kþ] to
high–normal in bradyarrhythmias). These pro-excitatory changes
may induce fibrillation or tachyarrhythmias.
As [Kþ]e increases still further, conduction velocity
decreases (broadening the P and QRS complexes) and the re-
fractory period increases, promoting cardiac conduction blocks.
As depolarization merges with (premature) repolarization,
there may be Q–T shortening (and apparent ST segment eleva-
tion) or the classic ‘sine wave’ ECG [64].
Thus hyperkalemia may manifest as any of various ECG
abnormalities: P, QRS, ST or T wave changes, resolution of
conduction blocks, new conduction blocks, asystole, atrial fi-
brillation, ventricular fibrillation or ventricular tachycardia.
However, the sensitivity and specificity of ECG changes for
hyperkalemia (and for cardiac death in hyperkalemia) are
poor, and there are many case reports of normal or near-
normal ECGs in patients with severe hyperkalemia [65, 67].
The pro-arrhythmogenic effects of hyperkalemia may be re-
versed by therapy with calcium (typically administered as chlo-
ride or gluconate salts) or sodium (typically as sodium
bicarbonate) [68, 69].
Peripheral neuropathy
The effects of hyperkalemia on myocardial excitability can
be dramatic, but there is emerging evidence that hyperkalemia
may also exert clinically important effects on neuronal excitabil-
ity. Median nerve conduction studies in hemodialysis patients
FIGURE 2: Mechanism of cardiac arrhythmia in hyperkalemia. In normokalemia, the cell membrane of the cardiomyocyte is polarized (resting
potential around 90mV). In moderate hyperkalemia, the cell membrane becomes partially depolarized, bringing the resting potential closer
to the threshold potential for AP initiation. Therefore fast sodium channels (Nav1.5) are activated more readily, increasing excitability and con-
duction velocity. This manifests as T wave peaking on the ECG as a mass of ventricular cardiomyocytes undergo (synchronous) early repolari-
zation. In severe hyperkalemia, voltage-dependent inactivation of Nav1.5 channels and activation of inwardly rectifying potassium channels
(Kir) lead to reductions in conduction velocity and can render cells refractory to excitation. This manifests as broadening of ECG complexes
and/or conduction blocks. This ﬁgure represents an idealized model, as there is poor correlation between ECG features and the degree of
hyperkalemia.
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have demonstrated pre-dialysis axonal depolarization (when se-
rum [Kþ] was 5.4mM) [70]. Using an elegant protocol in
which the nerve conduction studies were repeated after dialysis
against a high-dialysate [Kþ] (effectively a ‘potassium clamp’)
and again after dialysis against a low-dialysate [Kþ], Arnold
et al. [71] demonstrated that a normal electrophysiological pro-
file could be restored by lowering serum [Kþ] but not by the
clearance of other uremic toxins. They speculate that chronic
hyperkalemia could contribute to the pathogenesis of uremic
neuropathy and myopathy. In support of this, dietary potas-
sium restriction improved peripheral nerve function in patients
with CKD in a single-blind RCT [71].
Renal tubular acidosis
The combination of hyperkalemia and impaired renal acid
excretion is termed type IV renal tubular acidosis. In 1970s–
1990s, experiments in cultured cells, intact rodents, dogs and
humans demonstrated that hyperkalemia can impair ammonia-
genesis in the proximal renal tubule [72–74]. Because net renal
acid excretion is the sum of ammonium and titratable acid ex-
cretion minus bicarbonate excretion, this suggests that hyperka-
lemia per se could cause renal tubular acidosis. However, with
otherwise normal renal and adrenal function, acid–base
homoeostasis is maintained in hyperkalemia by compensatory
mechanisms (largely driven by increased aldosterone produc-
tion). Consequently, type IV RTA is invariably encountered
clinically in the context of hypoaldosteronism, either true or
functional [74].
Compelling evidence that hyperkalemia can cause renal tu-
bular acidosis was recently obtained from a mouse model of
PHAII [75]. These mice carry a mutation that drives constitu-
tive activation of the thiazide-sensitive co-transporter, NCC.
They exhibited hyperkalemia, hyperchloremic metabolic acido-
sis and reduced urinary ammonia excretion, phenomena that
were all corrected by dietary potassium restriction or thiazide
administration. Furthermore, this model was exploited to deter-
mine the molecular mechanisms whereby hyperkalemia
impairs renal ammonium excretion. Mice had reduced expres-
sion of ammoniagenic enzymes (phosphoenolpyruvate carbox-
ykinase and phosphate-dependent glutaminase) and increased
expression of an ammonia-recycling enzyme (glutamine syn-
thetase) in the proximal tubule, changes that would be expected
to result in reduced ammonia production. Expression of trans-
port proteins in the collecting duct (Rhcg and Hþ-ATPase) was
altered in a manner expected to reduce ammonia secretion into
the urine. These molecular changes were also corrected when
plasma [Kþ] was normalized with thiazide treatment.
Consequences of hyperkalemia in patients receiving
dialysis
Again, we can consider patients on dialysis as a special group
for two reasons: first, the prevalence of hyperkalemia (pre-dial-
ysis serum [Kþ] >5.5mM in 20% of hemodialysis patients)
and second, the prevalence of comorbidities that might potenti-
ate any risk of cardiac arrhythmia and death (e.g. left ventricular
hypertrophy) [57, 76].
In patients receiving maintenance hemo- and peritoneal di-
alysis, hyperkalemia has been associated with an increased risk
of all-cause mortality, cardiac arrhythmia and hospitalization
[56, 57, 76]. In hemodialysis, the risks of hyperkalemia may be
augmented during the long interdialytic gap. In an observa-
tional study of >50 000 hemodialysis patients, hyperkalemia
(>5.5mM pre-dialysis) was associated with an increased risk of
hospitalization in the subsequent 4 days and this risk was high-
est for [Kþ] measured on a Friday (i.e. before a 3-day gap)
than for [Kþ] measured on aMonday orWednesday (i.e. before
a 2-day gap) [76].
Changes in prescribing practice
Prescribing behaviour in hyperkalemia. The risk of hyper-
kalemia may deter physicians or patients from choosing certain
medications. For example, only 40% of eligible patients with
heart failure were prescribed an MRA in a Swedish registry of
>11 000 heart failure patients. Creatinine clearance <60mL/
min was associated with non-prescription of MRA therapy (but
serum [Kþ] was not) [77]. A systematic review of observational
and registry data from >80 000 patients with HFrEF estimated
that the ‘treatment gap’ (i.e. proportion of eligible patients who
were not prescribed treatments for HFrEF) was 13.1% for
ACEis/ARBs and 16.8% for MRAs and that renal failure was as-
sociated with non-prescription [78].
In an observational study of>190 000 UK patients with pre-
dialysis CKD Stages 3–5, serum [Kþ] exhibited a J-shaped rela-
tionship with rates of RASi discontinuation [79]. The adjusted
incidence rate ratios for RASi discontinuation if [Kþ] within
30days >6.0mM was 4.4 (compared with the reference cate-
gory 4.5–5.0mM). This value was 1.9 for [Kþ] 5.5–6.0mM.
Other significant associations with RASi discontinuation were
lower GFR, diabetes mellitus, use of diuretics and male sex.
Strategies to avoid ‘deprescribing’ in hyperkalemia. RASi
and MR antagonists might be legitimately withheld due to well-
justified fears of hyperkalemia in patients with significant risk
factors or in patients who prioritize avoidance of hyperkalemia
(or other factors such as tablet burden) over any potential prog-
nostic benefit. On the other hand, they may be withheld because
of an exaggerated fear of hyperkalemia on the part of the physi-
cian or patient. To our knowledge, there have been no robust
studies that have succeeded in exploring the underlying reasons
for this gap in a large population.
Several potential strategies could be used to minimize
‘deprescribing’ and thus realize the potential benefit of RASis
and MRAs in target patient groups. First, we could ensure that
prescribing decisions are made in the context of accurate data
regarding the presence—or risk—of hyperkalemia in any indi-
vidual patient. Large datasets have been used to construct
hyperkalemia ‘risk scores’ [44, 79]. Emerging technologies
(such as wearable and needle-free potassium sensors) providing
real-time [Kþ]e data could allow RASis/MRAs to be omitted
only on hyperkalemic days rather than being permanently dis-
continued in high-risk patients.
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Second, novel alternative drugs, such as non-steroidal MR
antagonists, may confer less risk of hyperkalemia than conven-
tional agents. These are being tested in clinical trials.
Third, one should not forget tried-and-trusted methods for
lowering potassium levels. Effective dietary advice and dietetic
input can play a vital role in limiting hyperkalemia.
Administration of loop and thiazide diuretics can be a useful
strategy in selected patients.
Finally, hyperkalemia could be avoided by the co-
prescription of tolerable potassium binders (patiromer or so-
dium zirconium cyclosilicate). This strategy was successful in
preventing RASi deprescribing in a small RCT [80]. So far, these
novel agents appear to be a valuable addition to our therapeutic
armoury. However, we should be relatively cautious about the
introduction into widespread clinical practice and remain vigi-
lant for side effects that may emerge during post-marketing sur-
veillance. In clinical trials, patiromer was associated with
adverse reactions including hypomagnesemia and gastrointesti-
nal upset and sodium zirconium cyclosilicate was associated
with hypokalemia and oedema [81, 82].
CONCLUSIONS
In classical models of potassium homoeostasis, aldosterone
exerts negative feedback control of renal potassium excretion.
There is an increasing appreciation that feedforward gut-to-
kidney signalling plays an important role.
Hyperkalemia occurs when renal potassium excretion is lim-
ited by reductions in GFR, tubular flow, distal sodium delivery
or the expression of (aldosterone-sensitive) ion transporters in
the distal nephron. Accordingly, the major risk factors
for hyperkalemia are renal failure, diabetes mellitus, adrenal
disease and the use of ACEis, ARBs or potassium-sparing
diuretics.
Hyperkalemia is associated with an increased risk of death
and this is explicable only in part by hyperkalemia-induced
cardiac arrhythmia. In addition to its well-established effects on
cardiac excitability, hyperkalemia may also contribute to pe-
ripheral neuropathy and cause renal tubular acidosis. Fear of
hyperkalemia might also contribute to the underprescription of
potentially beneficial medications, particularly in HFrEF. The
novel potassium binders may find a role in maximizing RASi
and MRA use in heart failure and proteinuric kidney disease.
We summarize the points that are most relevant for clinical
practice in Table 2.
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